EGFR and lung cancer: EGFR mutation‐positive lung cancer patients, for example, were found to not only be unresponsive to PD‐1/PD‐L1 inhibition (Calles et al, 2020) but even to hyper‐progress after immunotherapy (Kato et al, 2017).